UCI reports no doping cases from Tour de France

This is an archived article that was published on sltrib.com in 2013, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

Aigle, Switzerland • No riders tested positive for doping at the Tour de France, the International Cycling Union said Tuesday.

The testing program included 113 urine samples tested for EPO and 15 for steroids among the 622 samples. In blood analysis, 22 samples were tested for EPO-like substances, 18 for human growth hormone and two for transfusions.

"We don't have any adverse finding from the Tour de France," Francesca Rossi, director of the UCI-appointed Cycling Anti-Doping Foundation (CADF), said at a briefing.

The testing included 203 samples taken from riders in training and 419 during the three-week race, which was won by Chris Froome of Britain. A total of 443 blood samples and 179 urine samples were taken in a program jointly run by the UCI and the French anti-doping agency (AFLD). Most blood samples were used for comparisons to the biological passport system, which charts the blood levels of riders.

The total samples rose from 566 for the 2012 Tour, when only Frank Schleck of Luxembourg tested positive for a banned diuretic.

Tour riders who used banned drugs or doping methods could still be identified because stored samples can be analyzed again in the future using new or improved testing techniques.